People · Operator
Named in public records as an officer, director or promoter · active 2022–2024 · Biotechnology, Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NantBio, Inc. | — | Biotechnology | Series C | $180.1M | $856.7M | 2023 |
| Avenacy Inc. | — | Pharmaceuticals | Series B | $26.0M | $157.1M | 2024 |
| TooFon Inc | — | Other Technology | Series A | $4.4M | $46.3M | 2022 |
Douglas Reed Maughan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Douglas Reed Maughan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Soon-Shiong | 2 | 16 |
| Michael Borrus | 1 | 7 |
| Morteza Gharib | 1 | 5 |
| Charles Kenworthy | 1 | 4 |
| Patrick Shoon-Shiong | 1 | 3 |
| Jeffrey Yordon | 1 | 3 |
| Joe Reed Mase | 1 | 1 |
| Kam Phulwani | 1 | 1 |
| James Banaag | 1 | 1 |
| Sean Reed Brady | 1 | 1 |
| Amir Emadi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.